Mitogen-Activated Protein Kinase Phosphatase (MKP)-1 as a Neuroprotective Agent: Promotion of the Morphological Development of Midbrain Dopaminergic Neurons
- 525 Downloads
A greater understanding of the mechanisms that promote the survival and growth of dopaminergic neurons is essential for the advancement of cell replacement therapies for Parkinson’s disease (PD). Evidence supports a role for the mitogen-activated protein kinase p38 in the demise of dopaminergic neurons, while mitogen-activated protein kinase phosphatase-1 (MKP-1), which negatively regulates p38 activity, has not yet been investigated in this context. Here, we show that MKP-1 is expressed in dopaminergic neurons cultured from E14 rat ventral mesencephalon (VM). When dopaminergic neurons were transfected to overexpress MKP-1, they displayed a more complex morphology than their control counterparts in vitro. Specifically, MKP-1-transfection induced significant increases in neurite length and branching with a maximum increase observed in primary branches. We demonstrate that inhibition of dopaminergic neurite growth induced by treatment of rat VM neurons with the dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA) in vitro is mediated by p38 and is concomitant with a significant and selective decrease in MKP-1 expression in these neurons. We further show that overexpression of MKP-1 in dopaminergic neurons contributes to neuroprotection against the effects of 6-OHDA. Collectively, we report that MKP-1 can promote the growth and elaboration of dopaminergic neuronal processes and can help protect them from the neurotoxic effects of 6-OHDA. Thus, we propose that strategies aimed at augmenting MKP-1 expression or activity may be beneficial in protecting dopaminergic neurons and may provide potential therapeutic approaches for PD.
KeywordsMKP-1 Dopaminergic neuron p38 6-OHDA Growth Development
The authors would like to thank Ms Aisling Gavin for kindly providing us with tissue. This work was supported by the College of Medicine and Health, University College Cork, Science Foundation Ireland Grant No. SFI/RFP/NSC1298 (YN), Science Foundation Ireland Grant No. 10/RFP/NES2786 (GO’K), and the Irish Research Council for Science Engineering and Technology.
Conflict of interest
The authors declare that there are no conflicts of interest.
- Choi, W. S., Eom, D. S., Han, B. S., Kim, W. K., Han, B. H., Choi, E. J., et al. (2004). Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. The Journal of biological chemistry, 279(19), 20451–20460.PubMedCrossRefGoogle Scholar
- Crampton, S. J., Collins, L. M., Toulouse, A., Nolan, Y. M., & O’Keeffe, G. W. (2012). Exposure of foetal neural progenitor cells to IL-1beta impairs their proliferation and alters their differentiation—a role for maternal inflammation? Journal of Neurochemistry, 120(6), 964–973.PubMedGoogle Scholar
- Crocker, C. E., Khan, S., Cameron, M. D., Robertson, H. A., Robertson, G. S., & Lograsso, P. (2011). JNK inhibition protects dopamine neurons and provides behavioral improvement in a rat 6-hydroxydopamine model of Parkinson’s disease. ACS chemical neuroscience, 2(4), 207–212.PubMedCrossRefGoogle Scholar
- Davis, S., Vanhoutte, P., Pages, C., Caboche, J., & Laroche, S. (2000). The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. The Journal of neuroscience, 20(12), 4563–4572.PubMedGoogle Scholar
- Ding, Y. M., Jaumotte, J. D., Signore, A. P., & Zigmond, M. J. (2004). Effects of 6-hydroxydopamine on primary cultures of substantia nigra: Specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. Journal of Neurochemistry, 89(3), 776–787.PubMedCrossRefGoogle Scholar
- Gutierrez, H., O'Keeffe, G. W., Gavalda, N., Gallagher, D., & Davies, A. M. (2008). Nuclear factor kappa B signaling either stimulates or inhibits neurite growth depending on the phosphorylation status of p65/RelA. Journal of Neuroscience, 28(33), 8246–8256.Google Scholar
- Lawan, A., Shi, H., Gatzke, F., & Bennett, A. M. (2012). Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions. Cellular and Molecular Life Sciences, 70(2), 223–237.Google Scholar
- McKelvey, L., Gutierrez, H., Nocentini, G., Crampton, S. J., Davies, A. M., Riccardi, C. R., et al. (2012). The intracellular portion of GITR enhances NGF-promoted neurite growth through an inverse modulation of Erk and NF-kappaB signalling. Biology open, 1(10), 1016–1023.PubMedCrossRefGoogle Scholar
- Rajadhyaksha, A., Husson, I., Satpute, S. S., Küppenbender, K. D., Ren, J. Q., Guerriero, R. M., et al. (2004). L-Type Ca2 + channels mediate adaptation of extracellular signal-regulated kinase 1/2 phosphorylation in the ventral tegmental area after chronic amphetamine treatment. The Journal of neuroscience, 24(34), 7464–7476.PubMedCrossRefGoogle Scholar
- Ries, V., Silva, R. M., Oo, T. F., Cheng, H. C., Rzhetskaya, M., Kholodilov, N., et al. (2008). JNK2 and JNK3 combined are essential for apoptosis in dopamine neurons of the substantia nigra, but are not required for axon degeneration. Journal of Neurochemistry, 107(6), 1578–1588.PubMedCrossRefGoogle Scholar
- Slack, D. N., Seternes, O. M., Gabrielsen, M., & Keyse, S. M. (2001). Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1. The Journal of biological chemistry, 276(19), 16491–16500.PubMedCrossRefGoogle Scholar
- Staples, C. J., Owens, D. M., Maier, J. V., Cato, A. C., & Keyse, S. M. (2010). Cross-talk between the p38alpha and JNK MAPK pathways mediated by MAP kinase phosphatase-1 determines cellular sensitivity to UV radiation. The Journal of biological chemistry, 285(34), 25928–25940.PubMedCrossRefGoogle Scholar
- Takaki, M., Ujike, H., Kodama, M., Takehisa, Y., Nakata, K., & Kuroda, S. (2001). Two kinds of mitogen-activated protein kinase phosphatases, MKP-1 and MKP-3, are differentially activated by acute and chronic methamphetamine treatment in the rat brain. Journal of Neurochemistry, 79(3), 679–688.PubMedCrossRefGoogle Scholar